Newron (SIX: NWRN
) is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system.
According to a press release issued here on Tuesday, it was informed in the meeting of National Water Research Network (NWRN) held at Mehran University of Engineering and Technology (MUET) Jamshoro.
He briefed the participants regarding the establishment of NWRN and also shared aims and objectives of the U.S-Pakistan Centre for Advanced Studies in Water (USPCAS-W) established in Mehran University with the support of U.S.
The USPCASW will serve as the secretariat of the NWRN to facilitate the development and functioning of the network which will pave way for the broader network called Pakistan Water Sustainability Network (PWSN) to be established to seek the sustainable solution to water challenges in Pakistan, Dr.
29 July 2011 - Switzerland-based company Merck Serono, a division of Merck KGaA (ETR: MRK), and its partner Italian biopharmaceutical company Newron Pharmaceuticals SpA (SWF: NWRN
) announced today that patient enrollment has been completed in the SETTLE study.
29 June 2011 - Italy-based research and development company Newron Pharmaceuticals SpA (SWF: NWRN
) and its partner Merck Serono, a division of German Merck KGaA, announced today that they have completed patient enrollment in the MOTION1 study.
5 April 2011 - Italian drug maker Newron Pharmaceuticals (SWF: NWRN
) announced today that its net loss decreased to EUR20.5m (USD29.1m) for 2010, after a net loss of EUR23.5m for 2009.
15 February 2011 - Italy-based research and development company Newron Pharmaceuticals SpA (SWF: NWRN
) announced today that it has been advised by the Italian government's Ministero dell' Istruzione, dell' Universita e della Ricerca, that it is to receive a total payment of EUR3.7m (USD5m) with immediate effect, as part of a EUR5m grant for innovative R&D.
10 September 2010 - Newron Pharmaceuticals (SWF: NWRN
), an Italian firm listed in Switzerland, said its net loss expanded to EUR12.9m (USD16.4m) in the first half of 2010 from EUR8.4m in the prior-year period.
7 May 2010 - Italy-based and Swiss-traded Newron Pharmaceuticals SpA (VTX: NWRN
) announced yesterday top-line results from its SERENA study of ralfinamide in patients with at least moderate neuropathic low back pain (NLBP).
12 January 2010 - Swiss biopharmaceutical company Newron Pharmaceuticals SpA (SWF: NWRN
) said today it has randomised the last patient to treatment in its first Phase IIb/III study of ralfinamide in patients with at least moderate Neuropathic Low Back Pain (NLBP).
11 January 2010 - Swiss Newron Pharmaceuticals SpA (SWF: NWRN
) reported today an encouraging outcome from its Pre-IND and CTA meetings with the US Food and Drug Administration (FDA) and UK Medicines and Healthcare products Regulatory Agency (MHRA) regarding its novel new chemical entity, NW-3509, as an add-on to antipsychotics in patients with schizophrenia.